translation agency

FDA News
Approval of Edurant (rilpivirine) a new NNRTI for the treatment of HIV in treatment naive patients
Richard Klein & Kimberly Struble
May 20, 2011
Food and Drug Administration - May 20, 2011

On Friday, May 20, 2011, FDA approved Edurant (rilpivirine) 25 mg tablets, a new non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. Rilpivirine is an antiviral drug that helps to block reverse transcriptase, an enzyme necessary for HIV replication. The recommended dose of rilpivirine is one 25 mg tablet once daily taken orally with a meal.